Search results for "hazard ratio"

showing 10 items of 691 documents

Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analys…

2017

People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients (N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had significantly higher o…

medicine.medical_specialtyCardiovascular disease; bipolar disorder; cerebrovascular disease; congestive heart failure; coronary heart disease; major depression; premature mortality; schizophrenia; severe mental illness03 medical and health sciences0302 clinical medicinesevere mental illnessMedicineCardiovascular disease severe mental illness schizophrenia bipolar disorder major depression coronary heart disease cerebrovascular disease congestive heart failure premature mortalitycoronary heart diseasePsychiatrybipolar disorderFramingham Risk Scorebusiness.industryVascular diseaseIncidence (epidemiology)Hazard ratioCorrectionOdds ratiomedicine.diseaseCardiovascular disease030227 psychiatrycerebrovascular diseaseschizophreniaPsychiatry and Mental healthcongestive heart failurepremature mortalityHeart failureMajor depressive disorderPshychiatric Mental Healthbusinessmajor depressionBody mass index030217 neurology & neurosurgery
researchProduct

3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke…

2017

AIMS: Relatively little is known about the health outcomes associated with very low plasma concentrations of high density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We therefore investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study. METHODS AND RESULTS: Analysis was based on 21,751 participants from the REGARDS study who were fre…

medicine.medical_specialtyCholesterolProportional hazards modelbusiness.industryHazard ratioDiseasemedicine.diseaseConfidence intervalchemistry.chemical_compoundHigh-density lipoproteinchemistryInternal medicinemedicineCardiology and Cardiovascular MedicinebusinessStrokeDyslipidemiaEuropean Heart Journal
researchProduct

Chronic venous insufficiency, cardiovascular disease, and mortality: a population study

2021

Abstract Aims  Evidence regarding the health burden of chronic venous insufficiency (CVI), its clinical determinants, and impact on outcome is scarce. Methods and results  Systematic phenotyping of CVI according to established CEAP (Clinical-Etiologic-Anatomic-Pathophysiologic) classification was performed in 12 423 participants (age range: 40–80 years) of the Gutenberg Health Study from April 2012 to April 2017. Prevalence was calculated age- and sex-specifically. Multivariable Poisson regression models were calculated to evaluate the relation of CVI with cardiovascular comorbidities. Survival analyses were carried out to assess the CVI-associated risk of death. Replication of findings was…

medicine.medical_specialtyChronic venous insufficiencyEpidemiologyPopulationMECHANISMSInternal medicineEpidemiologymedicineVARICOSE-VEINSeducationRISKeducation.field_of_studybusiness.industryHazard ratioWOMENChronic venous insufficiencyASSOCIATIONmedicine.diseaseCardiovascular diseaseAll-cause mortalityComorbidityPREGNANCYATHEROSCLEROSISCohortPopulation studySurgeryCardiology and Cardiovascular MedicinebusinessCohort studyEuropean Heart Journal
researchProduct

Longterm Survival After Liver Transplantation for Autoimmune Hepatitis : Results From the European Liver Transplant Registry

2020

The aim of this study was to analyze longterm patient and graft survival after liver transplantation for autoimmune hepatitis (AIH-LT) from the prospective multicenter European Liver Transplant Registry. Patient and liver graft survival between 1998 and 2017 were analyzed. Patients after AIH-LT (n = 2515) were compared with patients receiving LT for primary biliary cholangitis (PBC-LT; n = 3733), primary sclerosing cholangitis (PSC-LT; n = 5155), and alcohol-related cirrhosis (AC-LT; n = 19,567). After AIH-LT, patient survival was 79.4%, 70.8%, and 60.3% and graft survival was 73.2%, 63.4%, and 50.9% after 5, 10, and 15 years of follow-up. Overall patient survival was similar to patients af…

medicine.medical_specialtyCirrhosismedicine.medical_treatmentCholangitis SclerosingMedizinAutoimmune hepatitis030230 surgeryLiver transplantationGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiving DonorsHumansProspective StudiesRegistriesTransplantationHepatologybusiness.industryLiver Cirrhosis BiliaryHazard ratioPatient survivalmedicine.diseasedigestive system diseasesLiver TransplantationHepatitis AutoimmuneIncreased risk030211 gastroenterology & hepatologySurgeryGraft survivalbusiness
researchProduct

Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure

2015

Abstract Objectives This study sought to examine the prognostic value of the soluble form of neprilysin (sNEP) in acute heart failure (AHF) and sNEP kinetics during hospital admission. Background sNEP was recently identified in chronic heart failure (HF) and was associated with cardiovascular outcomes. Methods A total of 350 patients (53% women, mean 72.6 ± 10.7 years of age) were included in the study. Primary endpoints were composites of cardiovascular death or HF hospitalizations at short-term (2 months) and long-term (mean: 1.8 ± 1.2 years) follow-up. sNEP was measured using an ad hoc–modified enzyme-linked immunosorbent assay, and its prognostic value was assessed using Cox regression …

medicine.medical_specialtyEjection fractionProportional hazards modelbusiness.industryHazard ratioProhormonemedicine.diseaseBrain natriuretic peptideGastroenterologyConfidence intervalHeart failureInternal medicinemedicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessNeprilysinmedicine.drugJACC: Heart Failure
researchProduct

Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐…

2020

Abstract Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on oral antihyperglycaemic drugs with an HbA1c of 9% or higher. Methods This retrospective cohort study assessed the impact of the timing of initiating both basal insulin and GLP‐1 RA therapies on reaching glycaemic targets (HbA1c < 7% and <8%, and ≥1% and ≥2% HbA1c reduction) over 12 months in people with markedly uncontrolled T2D (HbA1c ≥ 9%) on oral antihyperglycaemic drugs identified on the Optum Humedica database (electronic medical records; …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismInsulins030209 endocrinology & metabolismGlycemic ControlType 2 diabetes030204 cardiovascular system & hematologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyGLP‐1 analogueInternal medicinecohort studyInternal MedicineHumansHypoglycemic AgentsInsulinMedicinebasal insulinRetrospective StudiesGlycated Hemoglobindatabase researchbusiness.industryMedical recordHazard ratioRetrospective cohort studyOriginal Articlesmedicine.diseaseGlucagon-like peptide-1Confidence intervalglycaemic controlDiabetes Mellitus Type 2Pharmaceutical PreparationsCohortOriginal Articletype 2 diabetesbusinessCohort studyDiabetes, Obesity and Metabolism
researchProduct

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

2021

Abstract The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase statistical power for assessing treatment differences in efficacy and safety outcomes. Caplacizumab was associated with a significant reduction in the number of deaths (0 vs 4; P &amp;lt; .05) and a significantly lower incidence of refractory TTP (0 vs 8; P &amp;lt; .05) vs placebo during the treatment period. Consistent with the individual trials, treatment with caplacizumab resulted in a faster time to platelet count response (ha…

medicine.medical_specialtyExacerbationThrombotic thrombocytopenic purpura030204 cardiovascular system & hematologyPlaceboGastroenterology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRefractoryInternal medicinemedicineHumans610 Medicine &amp; healthAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryHazard ratioHematologySingle-Domain Antibodiesmedicine.diseaseStimulus ReportTolerability030220 oncology & carcinogenesisCaplacizumabbusinessBlood Advances
researchProduct

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

2009

Objective: Recent findings support greater efficacy of early vs. delayed interferon beta (IFN) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFN treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFN treatment with regard to the greatest benefits on disability progression. Methods: A cohort of 2,570 IFN-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. dela…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisHazard ratiomedicine.diseaseSurgeryCentral nervous system diseaseNeurologyInternal medicinePropensity score matchingCohortmedicineObservational studyNeurology (clinical)Unmeasured confoundingbusinessAnnals of Neurology
researchProduct

Prognostic Impact of 3-HM Concentration in Patients with Alcoholic or Viral Cirrhosis

2018

The role of endotoxemia related to intestinal bacterial translocation in worsening liver disease is the subject of many studies, but its impact on cirrhosis mortality has not been well evaluated. In this study, 3-hydroxymyristate (3-HM) (specific lipid of lipopolysaccharides) was directly quantified by an innovative patented assay with the aim of assessing the impact on cirrhosis mortality. The 3-HM concentration was measured in 593 patients with alcoholic or viral cirrhosis in stable clinical condition. A Cox hazards regression model was used to evaluate association between 3-HM and its fractions bound or nor bound to lipoprotein and the mortality. The 3-HM concentration was increased in p…

medicine.medical_specialtyGastrointestinal bleedingCirrhosisbusiness.industryHazard ratiomedicine.diseaseConfidence intervalHelsinki declarationLiver diseaseInternal medicineAscitesmedicinemedicine.symptomComplicationbusinessSSRN Electronic Journal
researchProduct

Mediterranean Diet and White Blood Cell Count—A Randomized Controlled Trial

2021

We aimed to assess the effects of the antioxidant-rich Mediterranean diet (MedDiet) on white blood cell count. Our study population included participants in the PREvención con DIeta MEDiterránea study (average age 67 years old, 58% women, high cardiovascular risk). We assessed whether a MedDiet intervention enriched in extra-virgin olive oil or nuts, versus a low-fat control diet, modified the incidence of leukocytosis (&gt

medicine.medical_specialtyHealth (social science)Mediterranean dietPlant ScienceTP1-1185030204 cardiovascular system & hematologyLower riskHealth Professions (miscellaneous)MicrobiologyGastroenterologyArticle03 medical and health sciences0302 clinical medicineMediterranean cookingpreventionWhite blood cellInternal medicineMediterranean dietCuina mediterràniamedicineLeukocytosisLeucocytes030304 developmental biology0303 health sciencesLeukopeniaLeucòcitsbusiness.industryIncidence (epidemiology)leukopeniaChemical technologyHazard ratioHematologic diseasesmedicine.anatomical_structureleukocytosisMalalties hematològiquesrandomized controlled trialPopulation studymedicine.symptombusinessFood Sciencewhite blood cell countFoods
researchProduct